Nom du produit:(+/-)-Narwedine

IUPAC Name:(1S,12S)-9-methoxy-4-methyl-11-oxa-4-azatetracyclo[8.6.1.0¹,¹².0⁶,¹⁷]heptadeca-6,8,10(17),15-tetraen-14-one

CAS:1668-86-6
Formule moléculaire:C17H19NO3
Pureté:95%
Numéro de catalogue:CM244272
Poids moléculaire:285.34

Unité d'emballage Stock disponible Prix($) Quantité
CM244272-250mg in stock ŽŽ
CM244272-1g in stock ǭƩŁ
CM244272-5g in stock ŽĜǭ

Pour une utilisation en R&D uniquement..

Formulaire de demande

   refresh    

Détails du produit

N° CAS:1668-86-6
Formule moléculaire:C17H19NO3
Point de fusion:-
Code SMILES:O=C1C=C[C@@]23CCN(C)CC4=CC=C(OC)C(O[C@@]3([H])C1)=C24
Densité:
Numéro de catalogue:CM244272
Poids moléculaire:285.34
Point d'ébullition:
N° Mdl:MFCD13193038
Stockage:

Column Infos

ZUNVEYL
Alpha Cognition announced that the FDA has granted approval for ZUNVEYL® (benzgalantamine) previously known as ALPHA-1062, for the treatment of mild-to-moderate Alzheimer’s disease. ZUNVEYL, a prodrug of AD treatment galantamine and an acetylcholinesterase inhibitor (AChEI), is postulated to exert its therapeutic effect by preventing the breakdown of acetylcholine, the important brain neurotransmitter involved in memory, motivation, and attention functions. The approval of ZUNVEYL is a pivotal moment in the fight against Alzheimer’s disease as it is only the second oral AD treatment to be approved in more than a decade.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.

Related Products